Intensive Studies for Recertification: Pediatric Pharmacy (Cert #L199021)

ACPE Numbers:
0204-9999-18-227-H01-P
0204-0000-18-288-H01-P
0204-0000-18-276-H01-P

Release Date: 02/06/2019
Expiration Date: 08/06/2019
Activity Type: Application-based
CE Credits: 4 hours
Activity Fee: $100 (ASHP member); $150 (non-member) 

Accreditation for Pharmacists

 The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These activities were recorded during a live educational event on December 3-4, 2018 at the Midyear Clinical Meeting in Anaheim, California. Learners who claimed credit for the live activities should not claim credit for these home study activities. 

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Drug therapy in critically ill pediatric patients
  • Pediatric pharmacotherapy
  • Pharmacogenomics

Activity Overview

The Intensive Study Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pediatric pharmacy. 

The Pediatric Pharmacy Intensive Study  Recertification Package consists of 3 activities (see table below) recorded during a live educational event on December 3-4, 2018 at the Midyear Clinical Meeting in Anaheim, Californiaand provides up to 4 hours of continuing pharmacy education and/or recertification credit.                                                                                                                                                                                  

These activities are part of the ASHP professional development program for BCPPS recertification approved by the BPS.  For pharmacists who maintain more than one certification, one of the activities is approved for several specialties (see table below). 

Recertification Credit*

Board certified pharmacists are eligible to receive up to 4 hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Participants who pass the assessments between February 6, 2019 – August 6, 2019, will be eligible for recertification credit for 2019. 

Learning Module

ACPE Number

Credit Hours

Specialty

*Assessment Pass Point

Expanding the Roles of Clinical Pharmacogenomics and Its Implementation*

0204-9999-18-227-H01-P

1.5

BCACP, BCCCP, BCGP, BCPPS, BCPS

71%

Optimizing Pediatric Pharmacotherapy Through the Use of Pharmacogenomics

0204-0000-18-288-H01-P

1

BCPPS

75%

Evidence-Based Decision Making in Selected Pediatric and Neonatal Critical Care Cases

0204-0000-18-276-H01-P

1.5

BCPPS

66%

Learning Objectives


Expanding the Roles of Clinical Pharmacogenomics and Its Implementation
*
0204-9999-18-227-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Recommend the key steps in the implementation of pharmacogenetics testing in clinical practice.
  • Evaluate strategies to initiate pharmacogenetic testing at your organization.
  • Given a case study, evaluate key elements of a pharmacogenomics testing product.
  • Given a case study, recommend appropriate pharmacogenomics resources based on specific needs in the implementation process.

This activity is approved for Board Certified Ambulatory Care Pharmacist (BCACP), Board Certified Critical Care Pharmacist (BCCCP), Board Certified Geriatric Pharmacist (BCGP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit. 

Optimizing Pediatric Pharmacotherapy Through the Use of Pharmacogenomics
0204-0000-18-288-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Analyze the role of the pediatric pharmacist in pharmacogenomics.
  • Apply pharmacogenetic test results to the care of pediatric patients.
  • Evaluate current pediatric pharmacy practice models that integrate pharmacogenomics.

This activity is approved for Board Certified Pediatric Pharmacy Specialist (BCPPS) recertification credit. 

Evidence-Based Decision Making in Selected Pediatric and Neonatal Critical Care Cases
0204-0000-18-276-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Select a first-line opioid and sedative infusion strategy for a patient in the neonatal intensive care unit (NICU) or the pediatric intensive care unit (PICU).
  • Given a patient case, develop a sedation and analgesia infusion regimen to prevent opioid tolerance and delirium in the NICU or PICU.
  • Given a patient case, determine the most appropriate inotrope or vasopressor for a patient with fluid-refractory shock.
  • Given a patient case, design a corticosteroid regimen for a patient with septic shock with adrenal insufficiency.
  • Given a patient case, determine the role of inhaled nitric oxide to treat a patient with a pulmonary hypertension crisis in the PICU.

This activity is approved for Board Certified Pediatric Pharmacy Specialist (BCPPS) recertification credit.

Faculty

Gillian C. Bell, Pharm.D.
Interim Director, Personalized Medicine
Mission Health
Asheville, North Carolina 

Henry Dunnenberger, Pharm.D., BCPS
Director – Pharmacogenomics
NorthShore University HealthSystem
Evanston, Illinois 

Roseann S. Gammal, Pharm.D., BCPS
Assistant Professor of Pharmacy Practice
MCPHS University
Boston, Massashusetts 

Kaitlin Hughes, Pharm.D., BCPPS
Clinical Pharmacist Pediatric Intensive Care
Riley Hospital for Children at IU Health
Indianapolis, Indiana 

Peter N. Johnson, Pharm.D., BCPPS, BCPS, FCCM, FPPAG
Associate Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Adjunct Associate
University of Oklahoma - College of Medicine
Oklahoma City, Oklahoma 

Evan Z. Ramsey, Pharm.D., BCPPS
Clinical Pharmacy Specialist and Residency Programs Director
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania 

Content Matter Experts

Christopher Betz, Pharm.D., BCPS, FASHP, FKSHP
Professor, Clinical and Administrative Sciences
Sullivan University College of Pharmacy
Louisville, Kentucky 

Kelly Epplen, Pharm.D., B.S.Pharm., BCACP, FASHP
Associate Professor of Clinical Pharmacy Practice
The James L. Winkle College of Pharmacy
University of Cincinnati
Cincinnati, Ohio 

Peter N. Johnson, Pharm.D., BCPPS, BCPS, FCCM, FPPAG
Associate Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Adjunct Associate
University of Oklahoma College of Medicine
Oklahoma City, Oklahoma 

Jamie L. Miller, Pharm.D., BCPPS, BCPS
Associate Professor
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma

Carolyn Oxencis, Pharm.D., BCOP, BCPS
Clinical Pharmacist, Hematology/Oncology
Froedtert & the Medical College of Wisconsin
Clinical Assistant Professor, Department of Clinical Sciences
Medical College of Wisconsin School of Pharmacy
Milwaukee, Wisconsin 

Ali Roberts, Pharm.D., BCPS
Medical Science Liaison II
Guardant Health
Redwood City, California 

Maria Shin, Pharm.D., BCGP, BCPS
Assistant Professor
Sullivan University College of Pharmacy
Louisville, Kentucky 

Paul M. Szumita, Pharm.D., BCCCP, BCPS, FASHP, FCCM
Clinical Pharmacy Practice Manager
Brigham and Women's Hospital
Foxboro, Massachusetts 

Jennifer L. Thackray, Pharm.D., BCPPS, BCPS
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York 

Reviewers

Holly L. Byrnes, Pharm D., BCPS
Susan R. Dombrowski, M.S., R.Ph.
Kristi Hofer, Pharm.D.
Robert Tremmel, Pharm.D., R.Ph. 

Field Testers

Manal Abouelkheir, Pharm.D., BCPPS, BCPS
April Anderson, Pharm.D., BCPPS
Suzan Assfour, M.S., BCPPS
Jennifer Banks, Pharm.D, BCACP, BCGP, BCPS, BC-ADM, CDE
Amanda Berger, Pharm.D., BCPPS
Monica Bogenschutz, Pharm.D, BCPPS, BCPS
Jesse Cramer, Pharm.D., BCPPS
Tasnim Dawoud , Pharm.D., BCPPS, BCPS
Michael Deanda, PharmD, BCPPS
Heather Dedman, B.Sc., BCPPS, BSP
Rou-Yee Chenhsu, Pharm.D., BCPPS, BCPS
Elizabeth Claire Elson, Pharm.D., BCPPS
Nicholas Farina, PharmD, BCCCP
Brian Ferullo, Pharm.D., BCGP
Erin Archibald-Hall, Pharm.D., BCPPS
Amy Holmes, Pharm.D., BCPPS
Carissa Jacobs, Pharm.D., BCPPS
Lindsay Kozar, Pharm.D., BCPPS
Biljana Lanier, B.S.Pharm., BCPPS
Suwen Lim, M.ClinPharm, BCACP, BCGP, BCOP, BCPS
Jane Mauro, Pharm.D., BCPPS, BCPS
Jordyn Metcalf, Pharm.D, BCPPS
Michael Raschka, Pharm.D., BCPPS
Colleen Teevan, Pharm.D., BCCCP, BCPS
Tara Smith, Pharm.D., BCPPS
Amy Mitchell-Van Steele, Pharm.D., BCPPS, AE-C
Jessica Wallace, Pharm.D., BCPPS
Juliana Zschoche, Pharm.D., BCPS 

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Henry Dunnenberger
    • Admera Health - Consultant, Honorarium
    • Veritas Genetics - Consultant
  • All other presenters, program chairs, planners, reviewers, staff, and others with an opportunity to control CE content, have nothing to disclose. 

Methods and CE Requirements

Activities consist of audio/ video/PDF files, an attestation statement, and activity evaluation. Learners must review all content and complete the attestation statement and course evaluation to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

*This activity was developed in partnership between ASHP and the American Pharmacists Association (APhA).